BR100 Increased By (0.01%)
BR30 Increased By (0.53%)
KSE100 Increased By (0.28%)
KSE30 Increased By (0.29%)
AGHA 6.38 Increased By ▲ 0.06 (0.95%)
BECO 4.35 Increased By ▲ 0.08 (1.87%)
BML 62.55 Increased By ▲ 0.10 (0.16%)
BOP 31.39 Increased By ▲ 0.16 (0.51%)
CNERGY 11.73 Increased By ▲ 0.14 (1.21%)
CSIL 5.91 Increased By ▲ 0.19 (3.32%)
FCCL 61.71 Increased By ▲ 0.17 (0.28%)
FFL 14.79 Decreased By ▼ -0.23 (-1.53%)
FNEL 1.24 Increased By ▲ 0.01 (0.81%)
KEL 6.32 Increased By ▲ 0.06 (0.96%)
KOSM 5.90 Increased By ▲ 0.34 (6.12%)
LOTCHEM 24.69 Increased By ▲ 0.01 (0.04%)
MLCF 103.93 Decreased By ▼ -0.15 (-0.14%)
NBP 173.32 Decreased By ▼ -1.96 (-1.12%)
NCPL 51.83 Decreased By ▼ -0.94 (-1.78%)
NPL 54.03 Decreased By ▼ -0.09 (-0.17%)
OGDC 315.87 Increased By ▲ 2.48 (0.79%)
PACE 9.26 Increased By ▲ 0.06 (0.65%)
PAEL 35.58 Decreased By ▼ -0.22 (-0.61%)
PIBTL 13.66 Increased By ▲ 0.19 (1.41%)
PPL 226.07 Increased By ▲ 4.26 (1.92%)
PRL 80.28 Increased By ▲ 1.20 (1.52%)
PTC 46.64 Decreased By ▼ -0.21 (-0.45%)
SSGC 23.82 Decreased By ▼ -0.05 (-0.21%)
TBL 9.24 Decreased By ▼ -0.07 (-0.75%)
TELE 7.55 Increased By ▲ 0.16 (2.17%)
TPL 24.54 Decreased By ▼ -0.57 (-2.27%)
TPLP 12.99 Increased By ▲ 0.48 (3.84%)
TREET 25.98 Decreased By ▼ -0.27 (-1.03%)
TRG 53.33 Decreased By ▼ -0.11 (-0.21%)
Business & Finance

Brazil approves Pfizer's COVID-19 shot, but has none to use

  • The Pfizer/BioNTech shot is the first vaccine against the novel coronavirus to receive full approval in Brazil, Anvisa said. Other vaccines developed by AstraZeneca and China's Sinovac Biotech Ltd, have only been approved for emergency use so far.
  • The approval is good news for a country whose immunization campaign has been plagued by delays and political squabbling.
Published Updated
By

SAO PAULO: Brazil has fully approved a COVID-19 vaccine developed by Pfizer Inc and BioNTech SE , health regulator Anvisa said on Tuesday, although it remains to be seen if Brasilia and Pfizer can end a dispute and agree a supply deal.

The Pfizer/BioNTech shot is the first vaccine against the novel coronavirus to receive full approval in Brazil, Anvisa said. Other vaccines developed by AstraZeneca and China's Sinovac Biotech Ltd, have only been approved for emergency use so far.

The approval is good news for a country whose immunization campaign has been plagued by delays and political squabbling. However, it is unclear whether the definitive approval of the vaccine will pave the way for a supply deal of a highly effective shot that is already being applied globally.

President Jair Bolsonaro has criticized the terms of a deal proposed by Pfizer, saying it is overly onerous on Brazil as it exempts the US firm from potential liability for unforeseen problems. Pfizer has said other countries, including neighbors in Latin America, have agreed to the terms.

Pfizer and Brazil's Health Ministry did not immediately respond to a request for comment.

Comments

Comments are closed for this article.